Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
about
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancerToward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challengesMonoclonal antibodies for the treatment of cancerEnhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancerAntibodies specifically targeting a locally misfolded region of tumor associated EGFRHigh Resolution NMR-based Model for the Structure of a scFv-IL-1 Complex: POTENTIAL FOR NMR AS A KEY TOOL IN THERAPEUTIC ANTIBODY DESIGN AND DEVELOPMENTStructural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH DomainsClinical potential of necitumumab in non-small cell lung carcinomaMethodologies for the isolation of alternative binders with improved clinical potentiality over conventional antibodies.Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor.Affinity Maturation of an Epidermal Growth Factor Receptor Targeting Human Monoclonal Antibody ER414 by CDR MutationFunctional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab.Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivoN-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes.Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recyclingNecitumumab: First Global Approval.Antibodies Targeting Closely Adjacent or Minimally Overlapping Epitopes Can Displace One AnotherNimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients wInteraction of antibodies with ErbB receptor extracellular regions.Targeting EGFR resistance networks in head and neck cancer.Targeting the EGF receptor ectodomain in the context of cancer.Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma.Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.Targeting the epidermal growth factor receptor in solid tumor malignancies.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.Necitumumab for non-small cell lung cancer.Molecular dynamics simulations of transitions for ECD epidermal growth factor receptors show key differences between human and drosophila forms of the receptors.Necitumumab for first-line treatment of advanced, squamous, non-small-cell lung cancer: a relevant step forward?Role of N-glycosylation in EGFR ectodomain ligand binding.Recent progress in protein-protein interaction study for EGFR-targeted therapeutics.Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin In East Asian Patients with Stage IV Squamous Non-Small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIREIn-depth analysis of subclass-specific conformational preferences of IgG antibodies.Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma.The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.Phage display-derived human antibodies in clinical development and therapyA simple contact mapping algorithm for identifying potential peptide mimetics in protein-protein interaction partners.A semi high-throughput method for screening small bispecific antibodies with high cytotoxicity2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA.
P2860
Q26852215-A05BFACA-1A69-4F37-891E-879B62A964A9Q26995399-1775BD87-7E54-4D4E-83DD-5ABFF7F9A5B4Q27025966-6261FCD8-EBC9-4392-A4BD-782E7664CBBDQ27305848-80EDDBC6-2DB1-4210-8645-40EBC25FD174Q27654155-D4F6D9F0-DE1F-4F3F-9F66-8BDBEC175DFBQ27657542-C25F1FB5-EDBC-47FE-942A-8DE6676EB049Q27678732-8935F00E-54AB-4A3C-AA84-8CA4EA16D633Q28072850-B1426FD5-D79B-4247-9096-086E14DA702DQ34220190-B5B40430-4275-4506-86F5-960015FB0D31Q34223866-8A839EC1-9754-4219-A828-912892E7AD26Q34455026-09E0AEB9-7152-40BA-A471-AB6989B2FBE8Q34504860-81781EB3-C4B7-4AA2-AC87-2D26A7368457Q35073267-8A08EBBF-7746-49F0-962F-15432F21BA96Q35378448-90D8DF1C-5995-4300-86C1-F823A707E7A1Q35842099-FBEADAEB-4E1F-4B21-8732-7ACDAE2217BBQ35884714-6BE1A29D-D3F8-430E-87E3-A283B0A09D47Q36242691-97AF0FAA-5D1E-4A8C-942D-685AAFB14417Q36517741-EC35F44F-490D-4E47-ACFF-6385B754D027Q37123936-DF5379D1-FBFB-47BA-B285-0CF7EF6B59F8Q37320814-6A962B2A-5541-4D8D-87C7-235CBD702060Q37405633-113CB40C-5421-4AC6-927B-7CF996BEE884Q37600910-86A4ED16-7C8E-4C12-AAA1-659B20B6423DQ37736496-E3BC705C-B82C-4CFD-B6EA-AB874609D74FQ37890404-CAB88FBD-8AEE-419E-A383-A78660C41999Q37990044-C9D0368E-FF56-4554-B177-D5879C13AE9CQ38214511-74A59A03-9928-447B-BF8B-B7E65B03655DQ38519582-7599C721-FAFD-4824-AE57-C73FF2F148A5Q38548814-C6027F00-676E-4AAA-AF6B-425D2A74264FQ38549559-DA1AEAFD-A091-4817-9916-86AD99A83EADQ38795554-CBC6C88B-0201-408A-A38C-0F4F456DEF06Q38899428-A3238A93-6C94-455C-8BB9-16EC57D541D0Q39006417-D02F54F0-7F29-4E05-B3CC-C418CA4F1755Q39051841-89899581-2411-4FDE-A1A3-536516029549Q39178484-477DCE86-7209-4E02-9EAA-E778DF08D472Q39385922-FD9F45FB-6A92-4356-904C-25E164BE936BQ39552974-B8B602F7-D862-406B-BCD3-D045BCAF41ABQ41416393-B7ADC954-96AF-46E6-BF6E-2998925E1032Q41837828-76738579-B89A-459F-BBF4-113105FAA5C2Q42128614-BE6E09E2-146E-4BF2-87F9-A5C7B5F9111FQ42333514-A045CA97-1C3E-49E4-B460-8965BADE637E
P2860
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
@ast
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
@en
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
@nl
type
label
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
@ast
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
@en
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
@nl
prefLabel
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
@ast
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
@en
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
@nl
P2093
P3181
P1433
P1476
Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
@en
P2093
Kathryn M Ferguson
Paul Kussie
Shiqing Li
P304
P3181
P356
10.1016/J.STR.2007.11.009
P577
2008-02-01T00:00:00Z